Literature DB >> 8946930

Internal tandem duplication of the flt3 gene found in acute myeloid leukemia.

M Nakao1, S Yokota, T Iwai, H Kaneko, S Horiike, K Kashima, Y Sonoda, T Fujimoto, S Misawa.   

Abstract

We analyzed mRNA expression of the flt3 gene in 30 patients with acute myeloid leukemia (AML) and 50 with acute lymphoblastic leukemia (ALL). Using reverse transcriptase-polymerase chain reaction (RT-PCR), expression of flt3 was observed in 61 patients; 22 (73%) with AML and 39 (78%) with ALL. Among these, five patients with AML (one M2, two M4, and two M5) showed unexpected longer transcripts with a primer combination which could amplify the transmembrane (TM) domain through the juxtamembrane (JM) domain. For those patients who expressed flt3 mRNA, the extracellular domain of the flt3 gene was also examined by RT-PCR, but no length abnormality was seen in this region. We further analyzed the TM domain through the second tyrosine kinase domain by genomic amplifications. The five patients who showed aberrant flt3 transcripts exhibited abnormal longer PCR products in addition to the germline products at a region corresponding to the JM through the first TK (TK1) domains. Sequence analyses of the abnormal RT-PCR products demonstrated that partial sequences were tandemly duplicated. Because all these altered transcripts were in-frame, deduced protein products could be expected. Sequence analyses of the genomic DNA revealed that three of the five patients showed a simple internal duplication within exon 11; one had an internal duplication (26 bp) with a 4-bp insertion; and in the fifth patient, a 136-bp sequence from the 3' part of exon 11 to intron 11 and the first 16-bp sequence of exon 12 were each duplicated with 1-bp insertion. In order to confirm the tumor specificity of these alterations, DNA samples obtained at complete remission were also analyzed in the three patients harboring an flt3 duplication, but no abnormal PCR product other than germline was detected in any of the samples. Our results suggest that an internal tandem duplication at the JM/TK1 domains of the flt3 gene is a somatic change detected preferentially in AML, possibly containing a monocytic component.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8946930

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  321 in total

1.  JAK2, complemented by a second signal from c-kit or flt-3, triggers extensive self-renewal of primary multipotential hemopoietic cells.

Authors:  Shengming Zhao; Karen Zoller; Masayoshi Masuko; Ponlapat Rojnuckarin; Xuexian O Yang; Evan Parganas; Kenneth Kaushansky; James N Ihle; Thalia Papayannopoulou; Dennis M Willerford; Tim Clackson; C Anthony Blau
Journal:  EMBO J       Date:  2002-05-01       Impact factor: 11.598

2.  Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay.

Authors:  Kathleen M Murphy; Mark Levis; Michael J Hafez; Tanya Geiger; Lisa C Cooper; B Douglas Smith; Donald Small; Karin D Berg
Journal:  J Mol Diagn       Date:  2003-05       Impact factor: 5.568

3.  Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse.

Authors:  Mark Levis; Farhad Ravandi; Eunice S Wang; Maria R Baer; Alexander Perl; Steven Coutre; Harry Erba; Robert K Stuart; Michele Baccarani; Larry D Cripe; Martin S Tallman; Giovanna Meloni; Lucy A Godley; Amelia A Langston; Sergio Amadori; Ian D Lewis; Arnon Nagler; Richard Stone; Karen Yee; Anjali Advani; Dan Douer; W Wiktor-Jedrzejczak; Gunnar Juliusson; Mark R Litzow; Stephen Petersdorf; Miguel Sanz; Hagop M Kantarjian; Takashi Sato; Lothar Tremmel; Debra M Bensen-Kennedy; Donald Small; B Douglas Smith
Journal:  Blood       Date:  2011-01-26       Impact factor: 22.113

Review 4.  Protein kinases: emerging therapeutic targets in chronic lymphocytic leukemia.

Authors:  Kumudha Balakrishnan; Varsha Gandhi
Journal:  Expert Opin Investig Drugs       Date:  2012-03-09       Impact factor: 6.206

5.  Different impact of intermediate and unfavourable cytogenetics at the time of diagnosis on outcome of de novo AML after allo-SCT: a long-term retrospective analysis from a single institution.

Authors:  H Nahi; M Remberger; M Machaczka; J Ungerstedt; J Mattson; O Ringden; Katarina Le-Blanc; P Ljungman; H Hägglund
Journal:  Med Oncol       Date:  2012-01-11       Impact factor: 3.064

6.  Down-regulation of microRNAs 222/221 in acute myelogenous leukemia with deranged core-binding factor subunits.

Authors:  Matteo Brioschi; John Fischer; Roberto Cairoli; Stefano Rossetti; Laura Pezzetti; Michele Nichelatti; Mauro Turrini; Francesca Corlazzoli; Barbara Scarpati; Enrica Morra; Nicoletta Sacchi; Alessandro Beghini
Journal:  Neoplasia       Date:  2010-11       Impact factor: 5.715

7.  NPM1, FLT3 and CEBPA mutations in pediatric patients with AML from Argentina: incidence and prognostic value.

Authors:  Patricia Rubio; B Campos; J A Digiorge; M S Gallego; A Medina; J G Rossi; M S Felice; C N Alonso
Journal:  Int J Hematol       Date:  2016-07-19       Impact factor: 2.490

8.  Mechanisms of apoptosis induction by simultaneous inhibition of PI3K and FLT3-ITD in AML cells in the hypoxic bone marrow microenvironment.

Authors:  Linhua Jin; Yoko Tabe; Hongbo Lu; Gautam Borthakur; Takashi Miida; Hagop Kantarjian; Michael Andreeff; Marina Konopleva
Journal:  Cancer Lett       Date:  2012-10-02       Impact factor: 8.679

9.  MUC1-C oncoprotein promotes FLT3 receptor activation in acute myeloid leukemia cells.

Authors:  Suiyang Liu; Li Yin; Dina Stroopinsky; Hasan Rajabi; Alexandre Puissant; Kimberly Stegmaier; David Avigan; Surender Kharbanda; Donald Kufe; Richard Stone
Journal:  Blood       Date:  2013-11-26       Impact factor: 22.113

Review 10.  Cytogenetics in acute myeloid leukemia.

Authors:  Claudia Schoch; Torsten Haferlach
Journal:  Curr Oncol Rep       Date:  2002-09       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.